Raymond James lowered the firm’s price target on Integer (ITGR) to $95 from $143 and keeps an Outperform rating on the shares after the stock tumbled 32% on news of headwinds from three customers limiting 2026 organic growth to LSD. The update came as a surprise to investors who were already skittish into the print, which actually saw reasonably solid Q3 results, the firm says. Sensitivity to customer confidentiality limits clarity, and Raymond thinks has further hindered the stock. While frustrating, the ...

文章核心观点 - 文章作者在约一年前认为Integer Holdings Corporation的股票在当时已被过度重估[1]

Key Takeaways Integer Holdings' Q3 adjusted EPS rose 25.2% to $1.79, beating the consensus estimate by 6.6%.Revenues grew 8.4% year over year to $467.7M, led by solid cardio and vascular segment performance.Despite strong results, ITGR shares fell more than 30% as 2026 guidance signaled slower revenue growth.Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.79 in the third quarter of 2025, which improved 25.2% year over year. The figure surpassed the Zacks Consensus Estim ...

Integer Holdings Corporation (NYSE:ITGR) reported better-than-expected earnings for the third quarter on Thursday.The company posted quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.68 per share. The company reported quarterly sales of $467.691 million which beat the analyst consensus estimate of $466.452 million.“Integer delivered another strong quarter of growth with sales up 8%, adjusted operating income up 14%, and adjusted EPS growth of 25%,” said Joseph Dziedzic, I ...

CANADA - 2025/10/23: In this photo illustration, the Integer Holdings Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesShares of Integer (NYSE: ITGR), a company specializing in the development and manufacturing of medical devices, saw a substantial decline of 32% on October 23, 2025. This notable drop was mainly due to the company’s updated financial projections for the remainder o ...

We recently published 10 Stocks Slump Amid Wall Street Cheer; 2 Hit Rock Bottom. Integer Holdings Corp. (NYSE:ITGR) is one of the worst performers on Thursday. Integer fell to an all-time low on Thursday, as investors sold off positions after lowering its outlook for full-year 2025 amid headwinds that are expected to similarly impact operations and margins next year. At intra-day trading, the stock dropped to its lowest 52-week price of $66.5 before paring losses to end the day just down by 32.28 percent ...

~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company’s Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of disting ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Integer (ITGR) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.55%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.57 per share when it actually produced earnings of $1.55, delivering a surprise of -1.27%.Over the last four ...

Integer (NYSE:ITGR) Q3 2025 Earnings Call October 23, 2025 09:00 AM ET Company ParticipantsAndrew Cooper - VP of Equity ResearchJoanne Wuensch - Managing DirectorJoe Dziedzic - President and CEOPayman Khales - President and CEO-electSanjiv Arora - SVP of Strategy, Business Development, and Investor RelationsSuraj Kalia - Managing DirectorTravis Steed - Managing Director and Equity ResearchNathan Treybeck - VP and Equity ResearchDiron Smith - EVP and CFOConference Call ParticipantsBrett Fishman - VP and Seni ...